Indraprastha Medical Corporation Limited (Indramedco) (NSE: INDRAMEDCO, BSE: 532150) is a New Delhi, Delhi-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹2,934 Cr, it ranks #1,056 by market cap among the 6,137 Indian listed companies on FinBizNet, and #16 of 42 in Hospitals and Healthcare Centers. At ₹299.80 (as of 25 Oct 2026), the share price is 53.2% below its 52-week high of ₹640.85 and 2.1% above its 52-week low of ₹293.65. The share price is down 45.9% over one year and down 17.8% over three months.
| Current Price | ₹299.80 |
|---|---|
| Market Cap | ₹2,934 Cr |
| NSE Symbol | INDRAMEDCO |
| BSE Code | 532150 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 15.8 |
| Return on Equity | 27.47% |
| Return on Assets | 15.18% |
| 52-Week Range | ₹293.65 – ₹640.85 |
| 1-Year Price Change | -45.9% |
| 3-Month Price Change | -17.8% |
| Beta (1Y) | 0.55 |
| Dividend Yield | 1.27% |
| Headquarters | New Delhi, Delhi |
| Website | www.apollohospitals.com/delhi/ |
| Revenue | ₹406 Cr |
|---|---|
| Net Profit | ₹56 Cr |
| Net Margin | 13.8% |
| EPS (Basic) | ₹6.09 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive med
1. Healthcare-This segment provides hospital services.
1. Healthcare-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,13,446 Cr | 57 | 21.50% | ₹7,044 Cr | -1.3% |
| Manipal Health Enterprises Ltd | ₹84,500 Cr | 82.1 | — | ₹3,091 Cr | — |
| Max Healthcare Institute Ltd | ₹82,242 Cr | 56.3 | 14.33% | ₹2,366 Cr | -30.7% |
| Aster Dm Healthcare Limited (Asterdm) | ₹58,702 Cr | 88.7 | 10.07% | ₹1,311 Cr | -7.8% |
| Fortis Healthcare Ltd. | ₹55,603 Cr | 53.3 | 11.01% | ₹2,545 Cr | -34.9% |
| Global Health Ltd (Medanta) | ₹33,340 Cr | 60 | 15.03% | ₹1,304 Cr | -15.1% |
| Krishna Institute Of Medical Science (KIMS) | ₹27,434 Cr | 112.5 | 9.72% | ₹1,180 Cr | -9.4% |
| Dr. Agarwal's Health Care Limited | ₹14,767 Cr | 112 | 8.31% | ₹614 Cr | -9.3% |
| Indraprastha Medical Corporation Limited (Indramedco) | ₹2,934 Cr | 15.8 | 27.47% | ₹406 Cr | -45.9% |
Listed by market capitalisation. Ratios are shown for context only.
Indraprastha Medical Corporation Limited (Indramedco) is trading at ₹299.80, with a market capitalisation of ₹2,934 Cr.
Indraprastha Medical Corporation Limited (Indramedco) operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Indraprastha Medical Corporation Limited (Indramedco) has a P/E of 15.8 and a return on equity of 27.47%.
Indraprastha Medical Corporation Limited (Indramedco) is listed on the NSE under the symbol INDRAMEDCO and on the BSE under the scrip code 532150.
Indraprastha Medical Corporation Limited (Indramedco)'s share price is down 45.9% over one year and down 17.8% over three months. Its 52-week range is ₹293.65 to ₹640.85.
In Q1 FY27, Indraprastha Medical Corporation Limited (Indramedco) reported revenue of ₹406 Cr and net profit of ₹56 Cr, with basic EPS of ₹6.09 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.